title: The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
abstract: OBJECTIVE
  Oral mucositis (OM) still represents a significant complication of hematopoietic stem cell transplantations (HSCT). Observational studies focusing on risk factor definitions are still warranted.
  
  
  METHODS
  A total of 126 patients participated in this observational study after autologous HSCT with the BEAM and HD-l-PAM 200mg/m(2) conditioning regimens. Basic clinical and laboratory variables and their impact on OM were assessed.
  
  
  RESULTS
  Age, gender, body mass index, and baseline absolute neutrophil counts were not shown to have any negative impact on OM development. The multivariate analysis revealed oral cryotherapy non-provision as being the most significant predictor for OM incidence (p < 0.0001), followed by BEAM conditioning regimen (p = 0.007), OM in a patient's history (p = 0.002) and lower number of days since the last chemotherapy (p = 0.025). The cryotherapy was remarkably effective both in the single high-dose melphalan 200mg/m(2) conditioning regimen (18% OM in cryotherapy vs. 68% without it, p<0.0001) and in the multidrug BEAM (melphalan 140mg/m(2)) regimen (38% vs. 86%, p=0.006).
  
  
  CONCLUSIONS
  Oral cryotherapy should be implemented into supportive care management in patients treated with high-dose melphalan short-infusion chemotherapy. Large and well-designed randomized trials are necessary to obtain more significant and reliable results and understanding regarding OM risk factors.
authors.affiliation: University Hospital Pilsen, Haematology-Oncology, Plzen, Czech Republic. vokurka@fnplzen.cz
authors.forename: Samuel
authors.initials: S
authors.lastname: Vokurka
authors.forename: Eva
authors.initials: E
authors.lastname: Bystricka
authors.forename: Jana
authors.initials: J
authors.lastname: Scudlova
authors.forename: Ewa
authors.initials: E
authors.lastname: Mazur
authors.forename: Maria
authors.initials: M
authors.lastname: Visokaiova
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Vasilieva
authors.forename: Renata
authors.initials: R
authors.lastname: Brandejsova
authors.forename: Ivana
authors.initials: I
authors.lastname: Chvojkova
authors.forename: Martina
authors.initials: M
authors.lastname: Vrabcova
authors.forename: Jitka
authors.initials: J
authors.lastname: Vitkova
authors.forename: Dagmar
authors.initials: D
authors.lastname: Mjartanova
authors.forename: Marcela
authors.initials: M
authors.lastname: Vodickova
authors.forename: Jana
authors.initials: J
authors.lastname: Bockova
authors.forename: Katerina
authors.initials: K
authors.lastname: Streinerova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D017679:Cryotherapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D013280:Stomatitis / Q000209:etiology / Q000517:prevention & control*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003561:Cytarabine; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine